The current read
BridgeBio has evolved from a pipeline-heavy rare-disease company into a multi-franchise commercial story, with substantially less clinical risk than the valuation debate still implies. Attruby is establishing a meaningful commercial anchor, while BBP-418, infigratinib and encaleret have each traversed most of their clinical-risk curves and could create three additional franchises over the next several years.
- Our preliminary SOTP supports modest upside from current levels, although the discount is not large: simultaneous launch execution, an expensive capital structure and the conversion of late-stage assets into durable commercial franchises now matter more than clinical proof-of-concept.